Receptagen Ltd. - A. Charles Morgan, Ph.D. Resigns
EDMONDS, Wash.--(BUSINESS WIRE)--Jan. 8, 1996--Receptagen Ltd.(TSE RCG., OTC
Bulletin Board RCEPF.) Receptagen Ltd. (TSE:RCG/OTCBB:RCEPF) announced that A. Charles
Morgan, Ph.D. has voluntarily resigned from his position as President of Receptagen Corporation,
Chief Technical Officer (C.T.O.) of Receptagen Ltd., as well as his board position, effective
immediately. Dr. Morgan, a co-founder of the Company, has been in service with the Company
since its incorporation in June 1992.
Warren Wheeler, President of Receptagen Ltd. stated, "We have enjoyed the benefits of having Dr.
Morgan both on the board and on the management team, and are sad to see him leave. His ability to
create new ideas and develop technological products will surely benefit his future endeavors. We
wish him well with his current plans and hope for his continued success."
Receptagen has been actively involved in three operations: Receptagen Corp. in Edmonds,
Washington, has been pursuing worldwide development of proprietary "Growth Blocker" drugs to
induce apoptosis (programmed cell death) in cancer cells; Ryan Pharmaceuticals Inc. in Edmonds,
Washington, owns the exclusive rights to U.S. commercialization of Coenzyme Q10 (CoQ10) for
use in treating AIDS symptoms; and VWD Distributors which is a wholesale drug and durable
medical equipment (DME) division in Burnaby, British Columbia, Canada.
The Toronto Stock Exchange has neither approved nor disapproved of the information contained
herein. |
